Pulmonology Xagena
Nintedanib is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of Nintedanib twice daily reduced lung-function decline and acute ...
A pre-specified subgroup analysis from the two replicate Phase III INPULSIS trials, presented at the European Respiratory Society International Congress ( ERS ), has shown Nintedanib slowed disease pr ...
The double blind, randomised and placebo-controlled IMPULSIS trials, involving 1,066 patients across 24 countries, evaluated the effect of oral Nintedanib 150 mg twice daily, on the annual rate of dec ...
The FDA ( Food and Drug Administration ) has approved Ofev ( Nintedanib ) for the treatment of idiopathic pulmonary fibrosis ( IPF ), a debilitating and fatal lung disease, which has a median survival ...
In the two replicate, placebo-controlled, 52-week, phase III INPULSIS trials, Nintedanib ( Ofev ) 150 mg twice daily significantly reduced the annual rate of decline in forced vital capacity ( FVC ), ...
Idiopathic pulmonary fibrosis ( IPF ) is a progressive disease characterised by dyspnea and loss of lung function. Using pooled data from the replicate, randomized, 52-week, placebo-controlled INPU ...
Idiopathic pulmonary fibrosis ( IPF ) is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause occurring in adults. Radiologic and/or histopathologic patterns are ...
In the phase III INBUILD trial Nintedanib ( Ofev ) has slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline in forced vital capacity ( FVC ...
